BioLife Solutions (NASDAQ:BLFS - Get Free Report) had its price target boosted by KeyCorp from $30.00 to $33.00 in a note issued to investors on Friday,Benzinga reports. The firm presently has an "overweight" rating on the medical equipment provider's stock. KeyCorp's price target suggests a potential upside of 23.60% from the company's previous close.
Several other analysts have also issued reports on the stock. HC Wainwright cut their price target on shares of BioLife Solutions from $29.00 to $27.00 and set a "buy" rating for the company in a research report on Monday, November 18th. Craig Hallum increased their target price on BioLife Solutions from $30.00 to $32.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. Finally, TD Cowen lifted their price target on BioLife Solutions from $28.00 to $31.00 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $28.29.
Get Our Latest Analysis on BLFS
BioLife Solutions Price Performance
BLFS traded down $0.02 on Friday, reaching $26.70. The stock had a trading volume of 365,400 shares, compared to its average volume of 383,235. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -25.19 and a beta of 1.91. BioLife Solutions has a fifty-two week low of $13.99 and a fifty-two week high of $28.88. The firm has a 50-day moving average of $24.62 and a 200-day moving average of $23.55.
Insider Buying and Selling at BioLife Solutions
In other news, CRO Garrie Richardson sold 3,070 shares of the firm's stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $25.12, for a total value of $77,118.40. Following the sale, the executive now directly owns 114,773 shares in the company, valued at approximately $2,883,097.76. This trade represents a 2.61 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Aby J. Mathew sold 25,000 shares of BioLife Solutions stock in a transaction on Friday, November 15th. The stock was sold at an average price of $21.17, for a total transaction of $529,250.00. Following the completion of the transaction, the executive vice president now directly owns 302,046 shares in the company, valued at $6,394,313.82. This represents a 7.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 71,313 shares of company stock valued at $1,572,899 in the last three months. Company insiders own 2.20% of the company's stock.
Hedge Funds Weigh In On BioLife Solutions
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mark Sheptoff Financial Planning LLC acquired a new stake in BioLife Solutions during the third quarter valued at $28,000. 1620 Investment Advisors Inc. acquired a new stake in shares of BioLife Solutions during the 2nd quarter valued at about $35,000. Quest Partners LLC acquired a new stake in shares of BioLife Solutions during the 3rd quarter valued at about $57,000. GAMMA Investing LLC increased its stake in shares of BioLife Solutions by 29.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider's stock valued at $83,000 after purchasing an additional 748 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new position in BioLife Solutions in the 2nd quarter worth about $122,000. Hedge funds and other institutional investors own 93.24% of the company's stock.
About BioLife Solutions
(
Get Free Report)
BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Featured Articles
Before you consider BioLife Solutions, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioLife Solutions wasn't on the list.
While BioLife Solutions currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
